EHA 2023 | Developing targeted therapies to address heterogeneity in AML

Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, comments on the heterogeneity of acute myeloid leukemia (AML) and how this impacts treatment approaches for patients. Dr Fathi explains that AML can involve different mutations and pathways across patients, but the primary treatment strategy remains to be intensive chemotherapy. Dr Fathi therefore notes that targeted therapies are currently being developed which could be combined with traditional treatments to reduce toxicity while maintaining high efficacy. To conclude, Dr Fathi highlights an ongoing Phase II multicenter study (NCT04801797) comparing intensive chemotherapy with the non-intensive azacitidine/venetoclax combination regimen in patients with AML. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.